AD109市場：市場規模、予測、新たな洞察-2032年

AD109は、1日1回就寝時に服用するファースト・イン・クラスの経口配合剤であり、幅広い重症度のOSA患者を対象とします。AD109は、選択的ノルエピネフリン再取り込み阻害薬（NRI）であるアトモキセチンと、新規のNCE選択的抗ムスカリン薬であるアロキシブチニンを組み合わせた薬剤です。この治験薬は、安全性、有効性、利便性に優れ、現在の標準治療の主要な限界に対処するように設計されています。

AD109は初期段階の臨床試験を完了しました。第II相臨床試験では、軽度から重度のOSA患者において、AD109は、試験の主要評価項目である患者の低酸素負荷（HB）において、プラセボと比較して統計学的に有意かつ臨床的に意味のある差を示しました。

AD109に加え、同社はAD504やいくつかの未公開プログラムなど、OSAのためのパイプラインにある他のいくつかの薬剤を持っています。一昨年（2021年～2022年）には、AD036、AD275、AD128もOSAのパイプラインにあっています。AD109プログラムは、ノルエピネフリン再取り込み阻害薬アトモキセチンと抗ムスカリン薬ラセミ体オキシブチニンを組み合わせたAD036で収集された追加臨床データによって支えられています。

今後数年間で、閉塞性睡眠時無呼吸症候群（OSA）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、AD109の優位性に影響を与える可能性のある機会を模索しています。OSAに対する他の新興製品がAD109に厳しい市場競争を挑むことが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における閉塞性睡眠時無呼吸症候群（OSA）治療薬のAD109市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 OSAにおけるAD109の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 AD109市場評価

• OSAにおけるAD109の市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国のOSAにおけるAD109の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: AD109, Clinical Trial Description, 2023
• Table 2: AD109, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: AD109 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: AD109 Market Size in the US, in USD million (2019-2032)
• Table 7: AD109 Market Size in Germany, in USD million (2019-2032)
• Table 8: AD109 Market Size in France, in USD million (2019-2032)
• Table 9: AD109 Market Size in Italy, in USD million (2019-2032)
• Table 10: AD109 Market Size in Spain, in USD million (2019-2032)
• Table 11: AD109 Market Size in the UK, in USD million (2019-2032)
• Table 12: AD109 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: AD109 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: AD109 Market Size in the United States, USD million (2019-2032)
• Figure 3: AD109 Market Size in Germany, USD million (2019-2032)
• Figure 4: AD109 Market Size in France, USD million (2019-2032)
• Figure 5: AD109 Market Size in Italy, USD million (2019-2032)
• Figure 6: AD109 Market Size in Spain, USD million (2019-2032)
• Figure 7: AD109 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: AD109 Market Size in Japan, USD million (2019-2032)

"AD109 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about AD109 for Obstructive sleep apnea (OSA) in the seven major markets. A detailed picture of the AD109 for OSA in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AD109 for OSA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AD109 market forecast analysis for OSA in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.

Drug Summary:

AD109 is a first-in-class, oral pharmaceutical combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI), atomoxetine, with a novel NCE selective antimuscarinic, aroxybutynin. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments.

AD109 has completed early-stage clinical trials. In a Phase II trial, patients with mild through severe OSA, AD109, had a statistically significant and clinically meaningful difference from placebo in the patients' hypoxic burden (HB), which was the study's primary endpoint. The company planned to initiate Phase III in 2022, but no further updates exist.

In addition to AD109, the company has a few other drugs in the pipeline for OSA, such as AD504 and some undisclosed programs. Year back (during 2021-2022), they also had AD036, AD275, and AD128 in their pipeline for OSA. The AD109 program is supported by additional clinical data collected with AD036, which consists of the norepinephrine reuptake inhibitor atomoxetine combined with the antimuscarinic, racemic oxybutynin.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AD109 description, mechanism of action, dosage and administration, research and development activities in Obstructive sleep apnea (OSA).
• Elaborated details on AD109 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AD109 research and development activities in OSA across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AD109.
• The report contains forecasted sales of AD109 for OSA till 2032.
• Comprehensive coverage of the late-stage emerging therapies for OSA.
• The report also features the SWOT analysis with analyst views for AD109 in OSA.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AD109 Analytical Perspective by DelveInsight

• In-depth AD109 Market Assessment

This report provides a detailed market assessment of AD109 for Obstructive sleep apnea (OSA) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• AD109 Clinical Assessment

The report provides the clinical trials information of AD109 for OSA covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Obstructive sleep apnea (OSA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AD109 dominance.
• Other emerging products for OSA are expected to give tough market competition to AD109 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AD109 in OSA.
• Our in-depth analysis of the forecasted sales data of AD109 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AD109 in OSA.

Key Questions:

• What is the product type, route of administration and mechanism of action of AD109?
• What is the clinical trial status of the study related to AD109 in Obstructive sleep apnea (OSA) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AD109 development?
• What are the key designations that have been granted to AD109 for OSA?
• What is the forecasted market scenario of AD109 for OSA?
• What are the forecasted sales of AD109 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to AD109 for OSA?
• Which are the late-stage emerging therapies under development for the treatment of OSA?

Table of Contents

1. Report Introduction

2. AD109 Overview in OSA

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AD109 Market Assessment

• 5.1. Market Outlook of AD109 in OSA
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of AD109 in the 7MM for OSA
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AD109 in the United States for OSA
  • 5.3.2. Market Size of AD109 in Germany for OSA
  • 5.3.3. Market Size of AD109 in France for OSA
  • 5.3.4. Market Size of AD109 in Italy for OSA
  • 5.3.5. Market Size of AD109 in Spain for OSA
  • 5.3.6. Market Size of AD109 in the United Kingdom for OSA
  • 5.3.7. Market Size of AD109 in Japan for OSA

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options